PATENT CLAIM ANALYSIS

Application Number: 16030046
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "233200"]

Abstract:
Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

Claim (Index 9):
The method of  claim 8 , wherein the compound has a formula selected from:

Metadata:
- Claim Count in Document: 8.0
- Percentile: 95.0
- Lexical Diversity: 1.34043
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15497783', '14302219', '13991321', '15748536', '14773686']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7934731828274121
- 35 USC 102 Novelty (BERT): 0.6434885006323117
- Combined Prediction Score: 0.7784747146079021
- Mean Citation Score: 410.139042
- Max Citation Score: 797.1224
- Similarity Product: 547.6175587603092

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test